Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Muscle-liver substrate fluxes in exercising humans and potential effects on hepatic metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Polygenic Risk Score Suggests Shared Genetic Architecture of Voice Break With Early Markers of Pubertal Onset in Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Gestational Diabetes Risk in Migrants. A Nationwide, Register-Based Study of all Births in Denmark 2004 to 2015

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

CONTEXT: The actions of both endogenous incretin hormones during a meal have not previously been characterized.

OBJECTIVE: Using specific receptor antagonists, we investigated the individual and combined contributions of endogenous glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) to postprandial glucose metabolism, energy expenditure, and gallbladder motility.

DESIGN: Randomized, double-blinded, placebo-controlled, crossover design.

SETTING: On four separate days, four liquid mixed meal tests (1894 kJ) over 270 minutes (min).

PATIENTS OR OTHER PARTICIPANTS: Twelve healthy male volunteers.

INTERVENTIONS: Infusions of the GIP receptor antagonist GIP(3-30)NH2 (800 pmol/kg/min), the GLP-1 receptor antagonist exendin(9-39)NH2 (0-20 min: 1000 pmol/kg/min; 20-270 min: 450 pmol/kg/min), GIP(3-30)NH2+exendin(9-39)NH2, or placebo/saline.

MAIN OUTCOME MEASURE: Baseline-subtracted area under the curve (bsAUC) of C-peptide.

RESULTS: Infusion of GIP(3-30)NH2+exendin(9-39)NH2 significantly increased plasma glucose excursions (bsAUC: 261 ± 142 mmol/L × min) during the liquid mixed meals compared with GIP(3-30)NH2 (180 ± 141 mmol/L × min; P = 0.048), exendin(9-39)NH2 (171 ± 114 mmol/L × min; P = 0.046), and placebo (116 ± 154 mmol/L × min; P = 0.015). Correspondingly, C-peptide:glucose ratios during GIP(3-30)NH2+exendin(9-39)NH2 infusion were significantly lower than during GIP(3-30)NH2 (P = 0.0057), exendin(9-39)NH2 (P = 0.0038), and placebo infusion (P = 0.014). GIP(3-30)NH2 resulted in significantly lower AUCs for glucagon than exendin(9-39)NH2 (P = 0.0417). Gallbladder ejection fraction was higher during GIP(3-30)NH2 compared with placebo (P = 0.004). For all interventions, energy expenditure and respiratory quotient were similar.

CONCLUSIONS: Endogenous GIP and GLP-1 lower postprandial plasma glucose excursions and stimulate insulin secretion but only endogenous GIP affects gallbladder motility. The two incretin hormones potentiate each other's effects in the control of postprandial glycemia in healthy men.

TidsskriftThe Journal of clinical endocrinology and metabolism
Udgave nummer3
StatusUdgivet - 1 mar. 2020

Bibliografisk note

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail:

ID: 59408825